

# Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study

## Supplementary Materials

**Stefan Esser,<sup>1</sup> Benoit Trottier,<sup>2</sup> Andrea Antinori,<sup>3</sup> Hila Elinav,<sup>4</sup> Antonio Antela,<sup>5</sup> Elif Tükenmez Tigen,<sup>6</sup> Marta Boffito,<sup>7</sup> John S. Lambert,<sup>8</sup> Berend J. van Welzen,<sup>9</sup> Frank Mack,<sup>10</sup> Sandra Schreiber,<sup>10</sup> Tali Cassidy,<sup>11</sup> Rebecca Harrison,<sup>11</sup> Taban Saifi,<sup>12</sup> Michael Sabranski,<sup>13</sup> Matteo Vassallo<sup>14,15</sup>**

<sup>1</sup>University Hospital Essen, Essen, Germany; <sup>2</sup>Clinique Médicale Urbaine du Quartier Latin, Montréal, QC, Canada; <sup>3</sup>National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy; <sup>4</sup>Hadassah University Medical Center, Jerusalem, Israel; <sup>5</sup>Hospital Clínico Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; <sup>6</sup>Marmara University Pendik Training and Research Hospital, Istanbul, Turkey; <sup>7</sup>Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; <sup>8</sup>Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland; <sup>9</sup>University Medical Centre Utrecht, Utrecht, The Netherlands; <sup>10</sup>Gilead Sciences GmbH, Bayern Munich, Germany; <sup>11</sup>Gilead Sciences Europe Ltd, Uxbridge, UK; <sup>12</sup>Gilead Sciences, Toronto, ON, Canada; <sup>13</sup>ICH Study Center, Hamburg, Germany; <sup>14</sup>Cannes General Hospital, Cannes, France; <sup>15</sup>CRCSEP Neurologie Pasteur 2, CHU de Nice, Université Cote d'Azur, UMR2CA (URRIS), Nice, France

# D/A/I Comedications Started Before Baseline

D/A/I medication (WHO generic drug names)	N	D/A/I medication (WHO generic drug names)	N
ALPRAZOLAM	5	MIRTAZAPINE	4
AMITRIPTYLINE	3	OLANZAPINE	1
BROMAZEPAM	2	OPIPRAMOL HYDROCHLORIDE	1
BROTIZOLAM	1	OXAZEPAM	1
BUPROPION HYDROCHLORIDE	4	PAROXETINE	2
CHLORAL HYDRATE	1	PRAZEPAM	1
CITALOPRAM	5	PREGABALIN	4
CLOMIPRAMINE HYDROCHLORIDE	1	PROMETHAZINE HYDROCHLORIDE	2
CLONAZEPAM	6	PROPRANOLOL HYDROCHLORIDE	1
DIAZEPAM	3	QUETIAPINE FUMARATE	4
DOXYLAMINE SUCCINATE	2	RISPERIDONE	1
DULOXETINE	6	SERTRALINE	7
ESCITALOPRAM	11	TEMAZEPAM	1
FLUNITRAZEPAM	1	TRAZODONE	6
FLUOXETINE HYDROCHLORIDE	3	TRIMIPRAMINE MALEATE	2
HYDROXYZINE	2	VENLAFAXINE	7
LAMOTRIGINE	1	ZOLPIDEM TARTRATE	7
LORAZEPAM	3	ZONISAMIDE	1
LORMETAZEPAM	1	ZOPICLONE	20
MIANSERIN HYDROCHLORIDE	1		<b>135</b>

# D/A/I AEs Reported Through 24 Months

AE	Action	Outcome
<b>Not related to B/F/TAF</b>		
More frequent dreams	Dose not changed	Recovered/resolved
Worsening of pre-existing chronic insomnia	Dose not changed	Recovering/resolving
Exacerbation of long-term anxiety	Dose not changed	Recovering/resolving
Social anxiety disorder	Dose not changed	Not recovered/not resolved
Panic attack	Dose not changed	Unknown
Insomnia	Dose not changed	Recovered/resolved
Sleep disturbances	Dose not changed	Recovered/resolved
Depression worsening	Dose not changed	Recovering/resolving
Insomnia	Dose not changed	Not recovered/not resolved
Insomnia	Dose not changed	Recovering/resolving
Increased anxiety	Dose not changed	Recovered/resolved with sequelae
Severe depressive episode without psychotic symptoms*	Dose not changed	Recovered/resolved
Sleep disorder	Dose not changed	Not recovered/not resolved
Depressive mode	Dose not changed	Recovered/resolved
Insomnia	Dose not changed	Not recovered/not resolved
Insomnia	Dose not changed	Recovering/resolving
Depression	Dose not changed	Recovered/resolved
Depression	Dose not changed	Unknown
Reactions to severe stress	Dose not changed	Not recovered/not resolved
Nervousness	Dose not changed	Not recovered/not resolved
Sleep disturbance	Dose not changed	Recovered/resolved
Anxiety	Dose not changed	Recovered/resolved
Worsening depression*	Dose not changed	Recovered/resolved
Difficulty getting to sleep	Dose not changed	Recovered/resolved
<b>Related to B/F/TAF</b>		
Worsening of anxiety	Drug withdrawn	Recovered/resolved
Colorful dreams	Dose not changed	Recovered/resolved
Sleeping disorder	Drug withdrawn	Recovered/resolved
Depression	Drug withdrawn	Recovered/resolved with sequelae
Insomnia	Drug withdrawn	Recovered/resolved with sequelae
Worsening of depression	Drug withdrawn	Not recovered/not resolved
Depressive exacerbation	Dose not changed	Recovered/resolved
Vivid dreams	Dose not changed	Recovered/resolved

Note: Nine individuals also experienced 10 other psychiatric AEs that were not classified as D/A/I AEs: possible chronic dysphoria, decreased libido, substance abuse, substance-induced psychosis, substance abuse (alcohol), aggressive state, psychiatric problems, adjustment disorders, somatization disorder, personality change (of these, aggressive state and personality change were classified as drug related, and personality-change AE also led to drug withdrawal).

\*SAE. AE, adverse event; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; D/A/I, depression and/or anxiety and/or insomnia; SAE, serious adverse event.